Jun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Liu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Lina Liu
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
26 shared publications - Shanshan Pei
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
26 shared publications - Amanda Winters
Children's Hospital Colorado, Aurora, CO 80045, USA
25 shared publications - Anagha Inguva. Sheth
Division of Hematology, University of Colorado Anschutz Medical Campus
25 shared publications - Anna E. Krug
Division of Hematology, Department of Medicine, University of Colorado Anschutz, Aurora, Colorado
25 shared publications - Austin E. Gillen
Division of Hematology, University of Colorado Anschutz Medical Campus, Aurora, CO
25 shared publications
Latest Publications
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is characterized by significant immunosuppression, limiting the efficacy of immunotherapy. Monocytic AML presents unique immunosuppressive features and constitutes a challenging subtype, necessitating focused investigation. Using single-cell multiomic analyses of primary AML samples, we revealed the immunosuppression landscape of monocytic AML and identified biliverdin reductase B (BLVRB) as a marker of immunosuppressive monocytic AML cells. BLVRB depletion downregulated immunomodulatory gene expression and sensitized AML cells to T-cell cytotoxicity, resulting in improved therapeutic efficacy in cell line–derived xenograft (CDX) and patient-derived xenograft (PDX) models. Mechanistically, BLVRB signals through the transcription factor MAFB to promote the expression of various immunosuppression-associated genes, resulting in inhibitory effects against anti-AML T cells. We further demonstrated that the small-molecule tamibarotene targets BLVRB, enhancing the efficacy of both chimeric antigen receptor (CAR) T and anti–PD-1 antibody therapies in AML. These findings elucidate the critical mechanism regulating immunosuppression in monocytic AML and identify BLVRB as a therapeutic target for improving AML immunotherapy. Significance: We revealed the particularly immunosuppressive feature of the monocytic AML subset and identified BLVRB-targeting strategies to reverse AML immunosuppression. Genetic disruption or pharmacologic inhibition of BLVRB sensitized AML cells to T cell–mediated cytotoxicity, offering potential strategies to enhance the therapeutic potency of immunotherapy against AML.
- 5 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF20
Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is characterized by significant immunosuppression, limiting the efficacy of immunotherapy. Monocytic AML presents unique immunosuppressive features and constitutes a challenging subtype, necessitating focused investigation. Using single-cell multiomic analyses of primary AML samples, we revealed the immunosuppression landscape of monocytic AML and identified biliverdin reductase B (BLVRB) as a marker of immunosuppressive monocytic AML cells. BLVRB depletion downregulated immunomodulatory gene expression and sensitized AML cells to T-cell cytotoxicity, resulting in improved therapeutic efficacy in cell line–derived xenograft (CDX) and patient-derived xenograft (PDX) models. Mechanistically, BLVRB signals through the transcription factor MAFB to promote the expression of various immunosuppression-associated genes, resulting in inhibitory effects against anti-AML T cells. We further demonstrated that the small-molecule tamibarotene targets BLVRB, enhancing the efficacy of both chimeric antigen receptor (CAR) T and anti–PD-1 antibody therapies in AML. These findings elucidate the critical mechanism regulating immunosuppression in monocytic AML and identify BLVRB as a therapeutic target for improving AML immunotherapy. Significance: We revealed the particularly immunosuppressive feature of the monocytic AML subset and identified BLVRB-targeting strategies to reverse AML immunosuppression. Genetic disruption or pharmacologic inhibition of BLVRB sensitized AML cells to T cell–mediated cytotoxicity, offering potential strategies to enhance the therapeutic potency of immunotherapy against AML.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Clinical information of primary AML specimens
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Clinical information of primary AML specimens
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
LSC gene expression signatures
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
LSC gene expression signatures
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Metabolomic analysis of m-LSC versus non m-LSC
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
Metabolomic analysis of m-LSC versus non m-LSC
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
List of specimens used for CITE-seq analysis
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
List of specimens used for CITE-seq analysis
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
WES analysis of AML subpopulations
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
WES analysis of AML subpopulations
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 3-5 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
List of commonly mutated genes in AML, Clinical information of VEN/AZA relapsed AML patients, CITE-seq and flow antibodies
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 3-5 from A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
List of commonly mutated genes in AML, Clinical information of VEN/AZA relapsed AML patients, CITE-seq and flow antibodies
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy
Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy
Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.